Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Anita Scheuber, MD, PhD
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors

November 22nd 2024

Anita Scheuber, MD, PhD, details how HPK1 inhibition may enhance the antitumor activity of ICIs in solid tumors, diving into the agent NDI-101150 in particular.

FDA
FDA Grants Fast Track Designation to ALE.P02 for CLDN1+ Squamous Solid Tumors

November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors
Repotrectinib Garners Positive CHMP Opinion for ROS1+ NSCLC and NTRK+ Solid Tumors

November 15th 2024

Revumenib in NPM1+ R/R AML | Image Credit: © LASZLO– stock.adobe.com
Revumenib Meets CR/CRh End Point in NPM1+ R/R AML

November 12th 2024

More News

Immunotherapy in Liver Cancer

Immunotherapy in Liver Cancer

September 8th 2017
Ongoing Clinical Trials in Second-Line HCC

Ongoing Clinical Trials in Second-Line HCC

September 8th 2017
Second-Line HCC: Unmet Needs

Second-Line HCC: Unmet Needs

September 8th 2017
HCC: Evolution of Frontline Treatment

HCC: Evolution of Frontline Treatment

September 8th 2017
Frontline Lenvatinib in HCC: Study 304

Frontline Lenvatinib in HCC: Study 304

September 8th 2017
Unmet Needs in Systemic Therapy for Liver Cancer

Unmet Needs in Systemic Therapy for Liver Cancer

September 8th 2017
Initial Treatment Decisions in Liver Cancer

Initial Treatment Decisions in Liver Cancer

September 8th 2017
Evidence With SIRT in HCC

Evidence With SIRT in HCC

September 8th 2017
Role of TACE in Liver Cancer

Role of TACE in Liver Cancer

September 8th 2017
Radiofrequency Ablation Vs Resection in HCC

Radiofrequency Ablation Vs Resection in HCC

September 8th 2017
HCC and Liver Transplantation

HCC and Liver Transplantation

September 8th 2017
Liver Cancer Screening Strategies

Liver Cancer Screening Strategies

September 8th 2017
Comorbidities and Management of HCC

Comorbidities and Management of HCC

September 8th 2017
Importance of Multidisciplinary Care in Liver Cancer

Importance of Multidisciplinary Care in Liver Cancer

September 8th 2017
Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

Maintenance Rucaparib Highly Effective Across Ovarian Cancer Subtypes

September 8th 2017

Maintenance treatment with the PARP inhibitor rucaparib improved median progression-free survival by 11.2 months compared with placebo for patients with BRCA-mutant platinum-sensitive ovarian cancer.

Mendelsohn's Antibody Research Reverberates Today

Mendelsohn's Antibody Research Reverberates Today

August 31st 2017

John Mendelsohn, MD, served as president of The University of Texas MD Anderson Cancer Center for a 15-year period that saw that institution’s size triple and its budget quadruple.

Liquid Biopsy for NSCLC: Emerging Developments

Liquid Biopsy for NSCLC: Emerging Developments

August 29th 2017
Future Directions for Liquid Biopsy in NSCLC

Future Directions for Liquid Biopsy in NSCLC

August 29th 2017
Liquid Biopsy and Next-Generation Sequencing

Liquid Biopsy and Next-Generation Sequencing

August 29th 2017
Interpretation of NSCLC Plasma Genotyping Results

Interpretation of NSCLC Plasma Genotyping Results

August 29th 2017
Liquid Biopsy: Differences Among Technologies

Liquid Biopsy: Differences Among Technologies

August 29th 2017
Plasma Genotyping Platforms: Strengths and Limitations

Plasma Genotyping Platforms: Strengths and Limitations

August 29th 2017
Plasma Testing for NSCLC EGFR & ALK Mutations

Plasma Testing for NSCLC EGFR & ALK Mutations

August 29th 2017
Clinical Applications for NSCLC Liquid Biopsy

Clinical Applications for NSCLC Liquid Biopsy

August 29th 2017
How Does Liquid Biopsy Work?

How Does Liquid Biopsy Work?

August 29th 2017
The Role for Liquid Biopsy in NSCLC

The Role for Liquid Biopsy in NSCLC

August 29th 2017
Widespread Mutation Testing for NSCLC

Widespread Mutation Testing for NSCLC

August 29th 2017
Genetic Testing for NSCLC

Genetic Testing for NSCLC

August 29th 2017
The Value of MRD Testing in Lymphoid Malignancies

The Value of MRD Testing in Lymphoid Malignancies

August 29th 2017

MRD Negativity in Multiple Myeloma

August 29th 2017
<1
...
505152535455565758
...
111>